Erector Spinae Plane Block Versus External Oblique Intercostal Plus Lateral External Oblique Muscle Plane Block in Laparoscopic Living Donor Nephrectomy
Comparison of Erector Spinae Plane Block and Combined External Oblique Intercostal and Lateral External Oblique Muscle Plane Blocks for Postoperative Analgesia After Laparoscopic Living Donor Nephrectomy: A Prospective, Randomized, Double-Blind Trial
Living kidney donors undergoing laparoscopic donor nephrectomy will be randomized to receive either an erector spinae plane block (ESPB) or a combination of external oblique intercostal (EOI) and lateral external oblique muscle plane (lateral EXOP) blocks at the end of surgery. The study aims to compare postoperative pain scores, opioid consumption, rescue analgesic requirement and postoperative nausea and vomiting between the two groups.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Laparoscopic living donor nephrectomy is associated with less postoperative pain than open surgery; however, trocar sites, the extraction incision and flank dissection can still cause substantial somatic and visceral pain. Results regarding the analgesic efficacy of ESPB in laparoscopic donor nephrectomy are conflicting, and sensory spread to the anterolateral abdominal wall after ESPB appears variable. The EOI block targets the lateral and anterior cutaneous branches of the T6-T10 intercostal nerves, and the lateral EXOP block targets the lateral cutaneous branches of T11-T12. As the trocar sites and the extraction incision are located on the anterolateral abdominal wall, we hypothesize that the combination of EOI and lateral EXOP blocks may provide more consistent analgesia than ESPB.
All donors will undergo transperitoneal laparoscopic donor nephrectomy, and the kidney will be extracted through the lower lateral trocar site as standard. Anesthesia will be induced with propofol, fentanyl and rocuronium and maintained with sevoflurane and remifentanil. Thirty minutes before the end of surgery, all patients will receive 1 g IV paracetamol, 100 mg IV tramadol and 8 mg IV ondansetron.
All blocks will be performed unilaterally on the surgical side under ultrasound guidance, after skin closure and before emergence from anesthesia, with the patient in the surgical lateral decubitus position. Each group will receive a total of 40 mL of 0.25% bupivacaine.
Group ESPB: the block will be performed at the T9 level, 2-3 cm lateral to the spinous process, with 40 mL of 0.25% bupivacaine injected deep to the erector spinae muscle.
Group EOI + lateral EXOP: the EOI block will be performed at the 6th rib level between the midclavicular and anterior axillary lines, with 20 mL of 0.25% bupivacaine injected between the external oblique and intercostal muscles. The lateral EXOP block will be performed on the mid-axillary line between the costal margin and the iliac crest, with 20 mL of 0.25% bupivacaine injected superficial to the external oblique muscle.
Postoperatively, all patients will receive 1 g IV paracetamol every 8 hours and fentanyl via IV patient-controlled analgesia (10 µg bolus, 10-minute lockout, no background infusion). Patients with NRS ≥4 despite PCA use will receive 0.5 mg/kg IV pethidine as rescue analgesia.
Because all blocks will be performed under general anesthesia, patients will be unaware of their group allocation. To maintain blinding, a standard dressing will be applied to all three potential block sites (paravertebral at T9, 6th rib level and lateral abdomen) in every patient. All postoperative assessments will be performed by an independent anesthesiologist who is not involved in block administration and is blinded to group allocation.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: ayse ince, assist proff
- Phone Number: 0905366774988
- Email: drayseince@gmail.com
Study Contact Backup
- Name: Bahadir Ciftci, Assoc. Prof.
- Phone Number: 0905343736865
- Email: bahadirciftci25@gmail.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Living kidney donors aged 18-65 years ASA physical status I-II Scheduled for elective pure transperitoneal laparoscopic donor nephrectomy Written informed consent
Exclusion Criteria:
Chronic pain or chronic opioid use Infection at the block site Allergy to local anesthetics Coagulopathy or anticoagulant use Body weight <50 kg Pregnancy Inability to use the NRS or PCA device Refusal to participate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Group ESPB
Unilateral ultrasound-guided ESPB at T9 on the surgical side with 40 mL of 0.25% bupivacaine, performed at the end of surgery before emergence. |
Unilateral ultrasound-guided erector spinae plane block performed on the surgical side at the T9 level after skin closure and before emergence from general anesthesia, with the patient in the lateral decubitus position. A linear probe will be placed 2-3 cm lateral to the spinous process in a parasagittal orientation. The needle will be advanced in-plane in a cranio-caudal direction until its tip lies between the erector spinae muscle and the transverse process. After hydrodissection with 5 mL of saline, 40 mL of 0.25% bupivacaine will be injected.
Other Names:
All patients will receive 1 g IV paracetamol and 100 mg IV tramadol 30 minutes before the end of surgery. Postoperatively, 1 g IV paracetamol will be given every 8 hours, and fentanyl will be delivered via IV patient-controlled analgesia (10 µg bolus, 10-minute lockout, no background infusion). Patients with NRS ≥4 despite PCA will receive 0.5 mg/kg IV pethidine as rescue analgesia.
Other Names:
|
|
Experimental: Group EOI and Lateral EXOP Combination
External oblique intercostal block and lateral external oblique muscle plane block combination will be applied. Unilateral ultrasound-guided EOI block at the 6th rib level (20 mL of 0.25% bupivacaine) and lateral EXOP block (20 mL of 0.25% bupivacaine) on the surgical side, performed at the end of surgery before emergence. |
All patients will receive 1 g IV paracetamol and 100 mg IV tramadol 30 minutes before the end of surgery. Postoperatively, 1 g IV paracetamol will be given every 8 hours, and fentanyl will be delivered via IV patient-controlled analgesia (10 µg bolus, 10-minute lockout, no background infusion). Patients with NRS ≥4 despite PCA will receive 0.5 mg/kg IV pethidine as rescue analgesia.
Other Names:
Unilateral ultrasound-guided blocks will be performed on the surgical side after skin closure and before emergence from general anesthesia. EOI block: the probe will be placed at the 6th rib level between the midclavicular and anterior axillary lines in a paramedian sagittal-oblique orientation, and 20 mL of 0.25% bupivacaine will be injected between the external oblique and intercostal muscles. Lateral EXOP block: the probe will be placed on the mid-axillary line between the costal margin and the iliac crest, and 20 mL of 0.25% bupivacaine will be injected superficial to the external oblique muscle. Correct needle tip position is confirmed with 5 mL of saline before each injection. Total volume: 40 mL of 0.25% bupivacaine.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain score at 8th hour
Time Frame: 8 hours after PACU admission
|
Pain intensity at rest assessed with the Numeric Rating Scale (0 = no pain, 10 = worst imaginable pain) |
8 hours after PACU admission
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cumulative fentanyl consumption
Time Frame: 0-24 hours postoperatively
|
Total fentanyl given via IV PCA (µg). |
0-24 hours postoperatively
|
|
Pain scores at rest and on coughing
Time Frame: 0, 2, 4, 8, 12 and 24 hours postoperatively.
|
Pain scores at rest and on coughing will be recorded based on NRS (0-10). |
0, 2, 4, 8, 12 and 24 hours postoperatively.
|
|
Time to first rescue analgesic
Time Frame: 0-24 hours postoperatively.
|
Time from PACU admission to the first pethidine dose given for NRS ≥4. |
0-24 hours postoperatively.
|
|
Incidence of postoperative nausea and vomiting.
Time Frame: 0-24 hours postoperatively.
|
Number of patients with any nausea or vomiting episode will be recorded. |
0-24 hours postoperatively.
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Chin KJ, El-Boghdadly K. Mechanisms of action of the erector spinae plane (ESP) block: a narrative review. Can J Anaesth. 2021 Mar;68(3):387-408. doi: 10.1007/s12630-020-01875-2. Epub 2021 Jan 6.
- Ergun M, Berkers AW, van der Jagt MF, Langenhuijsen JF, van Ozdemir-Brunschot D, van der Vliet JA, D'Ancona FC, Warle MC. Components of pain assessment after laparoscopic donor nephrectomy. Acta Anaesthesiol Scand. 2014 Feb;58(2):219-22. doi: 10.1111/aas.12236. Epub 2013 Dec 6.
- Ozkalayci O, Karakaya MA, Yenigun Y, Cetin S, Darcin K, Akyollu B, Arpali E, Kocak B, Gurkan Y. Effects of erector spinae plane block on opioid consumption in patients undergoing hand-assisted laparoscopic donor nephrectomy: a randomized controlled trial. Minerva Anestesiol. 2024 Mar;90(3):154-161. doi: 10.23736/S0375-9393.23.17706-6. Epub 2024 Feb 2.
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Nervous System Diseases
- Postoperative Complications
- Pathologic Processes
- Neurobehavioral Manifestations
- Perceptual Disorders
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Pain, Postoperative
- Agnosia
- Organic Chemicals
- Lipids
- Anilides
- Amides
- Aniline Compounds
- Amines
- Acetanilides
- Alcohols
- Cyclohexanols
- Hexanols
- Fatty Alcohols
- Dimethylamines
- Methylamines
- Acetaminophen
- Tramadol
Other Study ID Numbers
Other Study ID Numbers
- Medipol 9
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
There is no plan to make individual participant data available
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.